Business
Harrow Launches Next-Generation Compounded Atropine Formulations
Formulations Do Not Contain Preservatives or Boric Acid, Have a Physiologic pH of 5.5, and May Be Stored at Room Temperature For Up to 180 Days NASHVILLE,
About this update from Harrow, Inc.
[{"type":"text","content":"\nFormulations Do Not Contain Preservatives or Boric Acid, Have a Physiologic pH of 5.5, and May Be Stored at Room Temperature For Up to 180 Days\n\n NASHVILLE, Tenn.--(BUSINESS WIRE)--\nHarrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of its patent-pending, next-generation compounded Atropine formulations, which are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx.\n\nIn commenting on the announcement, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, “Our mission has always been to help our eyecare professionals address their patients’ unmet needs and to make ophthalmic medications both accessible and affordable. The availability of these innovative compounded atropine formulations is in keeping with our mission. We believe ophthalmologists, optometrists, and the millions of Americans who may benefit from topical atropine therapy, will appreciate the tremendous value these patent-pending formulations offer.”\n\nKey Attributes of the ImprimisRx Next-Generation Atropine Formulations:\n\n\nUndergo validated analytical tests to ensure consistency, potency, and stability.\n\n\nDo not contain either preservatives or boric acid.\n\n\nHave a physiologic pH of 5.5.\n\n\nMay be stored at room temperature for up to 180 days.\n\n\nEyecare professionals can order these new compounded atropine formulations for as low as $39 per 5mL bottle – either online at atropine.com or by calling or texting 615‑437‑4690 to speak to ImprimisRx Customer Service.\n\nCompounded formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. Compounded medications are not reviewed by the FDA for safety or efficacy. ImprimisRx does not compound copies of commercially available products.\n\nPLEASE REVIEW THE ATROPINE PACKAGE INFORMATION BEFORE USING.\n\nAbout Harrow\n\nHarrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten (10) FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding busin...